Thermo Fisher Scientific Oncomine Dx Target Test Gets Expanded Regulatory Approval in Japan

Feb 26, 2019

|

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that Japan's Ministry of Health, Labor, and Welfare has granted expanded approval to its Oncomine Dx Target Test CDx System.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

Unifying QuantideX NGS DNA and RNA Panels: Methods for Detecting Cancer Hotspots, SNVs, INDELs and Gene Fusions on a Single Flow Cell

Mar

11

Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar

23

Featured Webinar

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

This webinar will discuss findings from the study, in which molecular residual disease (MRD) was assessed using circulating tumor DNA (ctDNA) without prior mutational knowledge in oligometastatic colorectal cancer (CRC) patients who had received neoadjuvant chemotherapy. This study also investigated urine as an alternative analyte for ctDNA MRD detection.

Mar

25

Featured Webinar

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.

Apr

08

Featured Webinar

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.

Menu

Thermo Fisher Scientific Oncomine Dx Target Test Gets Expanded Regulatory Approval in Japan

To read the full story....

Breaking News

CHMP Recommends Approval of GSK's Dostarlimab in Endometrial Cancer

In Brief This Week: Kura Oncology, Innovent Biologics, Iaso Biotherapeutics, Invitae, Hologic

Novartis Licenses BeiGene's Anti-PD-1 Agent Tislelizumab in North America, Europe, Japan

European Groups Find Inequitable Access to Quality Cancer Biomarker Testing

Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing

Celcuity Prices Upsized Public Stock Offering, Anticipates $24M in Proceeds

Featured White Papers

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

ctDNA MRD Detection and Personalized Oncogenomic Analysis in Colorectal Cancer

Virtual Molecular Tumor Board Series: What to Do with a ‘Negative’ Molecular Panel Case

Interpretation of Comprehensive Genomic Profiling from ctDNA Through Clinical Decision Support

What's Popular?

Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year

Personal Genome Diagnostics to Build Commercial Infrastructure, Drive Partnerships With New Funding

FDA Approves Regeneron, Sanofi's Libtayo With Agilent PD-L1 CDx in Frontline NSCLC

Qiagen, Inovio Expand CDx Partnership, Starting With NGS Test for Cervical Dysplasia Therapy

Biocept, Protean BioDiagnostics Team up to Study EGFR Assay in Lung Cancer

Sponsorships